Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Z. Nikolova
Phase Ib Study of Cc-122 in Combination With Obinutuzumab (Ga101): Relapsed or Refractory (R/R) Patients With B-Cell Non-Hodgkin Lymphomas (Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Rare KIT (CD117) Expression in Multiple Myeloma Abrogates the Usefulness of Imatinib Mesylate Treatment
Virchows Archiv
Medicine
Forensic Medicine
Pathology
Cell Biology
Molecular Biology
Related publications
VENETOCLAX (VEN), BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): FINAL RESULTS OF a PHASE I STUDY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Clinical Activity of Regn1979, an Anti-Cd20 X Anti-Cd3 Bispecific Antibody (Ab) in Patients (Pts) With (W/) Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Venetoclax (Ven) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Polatuzumab Vedotin (Pola) + Obinutuzumab (G) + Lenalidomide (Len) in Patients (Pts) With Relapsed/Refractory (R/R) Follicular Lymphoma (Fl): Phase Ib/Ii Interim Analysis
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Interim Report From a Phase 2 Multicenter Study of Tazemetostat, an Ezh2 Inhibitor, in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase Ii Study of Lenalidomide and Rituximab (R²) Combination in Patients With High-Risk Refractory/Relapsed Diffuse Large B-Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
A Phase I Trial of 19-28z Car-T Cells Post-High Dose Therapy and Autologous Transplantation (Hdt-Asct) for Relapsed and Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-Nhl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase I Study of CC-486 Alone and in Combination With Carboplatin or Nab‑paclitaxel in Patients With Relapsed or Refractory Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
